Leading stem cell and exosome therapy research blog by Cell La Vie, Bangkok. Clinical insights, cost breakdowns, and regenerative treatment guides.
MSCs are the most promising cell therapy in progressive MS, and 2026 added the mechanism papers and one well-controlled trial that finally make the case. Here’s what 17 trials, SMART-MS, and the new miRNA work mean for real patients.
Read More »
Eight 2026 studies detail how MSC exosomes inhibit ferroptosis, deliver sustained paracrine signaling via hydrogels, and improve LVEF in rat MI models. Here is what translational researchers need to know before the first Phase 2 exosome trial reads out.
Read More »
Discover the groundbreaking potential of MSC-derived exosomes in revolutionizing Rheumatoid Arthritis immunotherapy. Learn about novel nanoplatforms and their mechanism of action.
Read More »
2026 medical update on MSC therapy for diabetic foot ulcers: M2 macrophage polarization, EXO-miR3671 angiogenesis, hydrogel delivery, UC-MSC vs ADSC head-to-head, 47-RCT meta-analysis, and cost-effectiveness vs amputation in Thailand.
Read More »
2026 Q3 update on allogeneic vs autologous MSC: head-to-head trial data, donor-age impact, 2026 manufacturing advances, when each is preferred, the cost picture, and FAQ for patients in Thailand and Asia-Pacific.
Read More »
Osteoporosis after menopause affects millions of women. New 2026 research shows mesenchymal stem cells and exosomes can rebuild bone density safely. Here’s what patients need to know.
Read More »
Explore the latest 2026 research on stem cell therapy for dry Age-Related Macular Degeneration (AMD). Learn how RPE cell transplantation and clinical trials offer new hope for restoring vision. Consult Cell La Vie.
Read More »
New 2026 research reveals UC-MSC exosomes combined with low-intensity pulsed ultrasound and curcumin-hydrogel systems achieve remarkable burn wound healing — including MRSA-infected wounds — through autophagy regulation, anti-scarring mechanisms, and immunomodulation. Five landmark papers reviewed.
Read More »
2026 patient guide to MSC therapy for Alzheimer’s disease: how it differs from lecanemab and donanemab, who is a candidate, what outcomes to expect, the 6 active clinical trials including NCT06775964 and the first MSC + antibody drug combination trial.
Read More »Zimislecel (VX-880) is the first stem cell-derived islet therapy to reach the FDA, and the September 2025 NEJM paper showed 12 of 12 patients achieving insulin independence. Here’s what it means for T1D patients in 2026, who qualifies, and what options exist in Thailand now.
Read More »
5 MSC and exosome trials for psoriasis have reported completion; three 2026 mechanistic studies reveal novel Ang1/Tie2 angiogenesis mechanisms, engineered exosome-nanoparticle platforms, and culture medium optimization for psoriasis-specific MSC potency.
Read More »